NO20050782L - Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte - Google Patents

Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte

Info

Publication number
NO20050782L
NO20050782L NO20050782A NO20050782A NO20050782L NO 20050782 L NO20050782 L NO 20050782L NO 20050782 A NO20050782 A NO 20050782A NO 20050782 A NO20050782 A NO 20050782A NO 20050782 L NO20050782 L NO 20050782L
Authority
NO
Norway
Prior art keywords
alpha
pain
treatment
delta ligand
synergistic combination
Prior art date
Application number
NO20050782A
Other languages
English (en)
Inventor
Mark John Field
Richard Griffith Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20050782L publication Critical patent/NO20050782L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

2005-04-08 S a m m e n d r a g Det beskrives en kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for bruk innen terapi, særlig innenfor den kurative, profylaktiske eller palliative behandling av smerte, særlig neuropatisk smerte. Særlig foretrukne alfa-2deltaligander er gabapentin og pregabalin. Særlig foretrukne PDEV-inhibitorer er sildenafil, vardenafil og tadalafil.
NO20050782A 2002-08-15 2005-02-14 Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte NO20050782L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219024.7A GB0219024D0 (en) 2002-08-15 2002-08-15 Synergistic combinations
PCT/IB2003/003476 WO2004016259A1 (en) 2002-08-15 2003-08-04 Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain

Publications (1)

Publication Number Publication Date
NO20050782L true NO20050782L (no) 2005-04-08

Family

ID=9942388

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050782A NO20050782L (no) 2002-08-15 2005-02-14 Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte

Country Status (40)

Country Link
EP (1) EP1536782B1 (no)
JP (1) JP2006502139A (no)
KR (2) KR20050042154A (no)
CN (1) CN1674884A (no)
AP (1) AP2005003227A0 (no)
AR (1) AR040871A1 (no)
AT (1) ATE359775T1 (no)
AU (1) AU2003249476B2 (no)
BR (1) BR0313484A (no)
CA (1) CA2495433A1 (no)
CR (1) CR7687A (no)
DE (1) DE60313330T2 (no)
DK (1) DK1536782T3 (no)
EA (1) EA007504B1 (no)
EC (1) ECSP055593A (no)
ES (1) ES2285230T3 (no)
GB (1) GB0219024D0 (no)
GE (1) GEP20084366B (no)
GT (1) GT200300173A (no)
HN (1) HN2003000247A (no)
HR (1) HRP20050136A2 (no)
IL (1) IL166415A0 (no)
IS (1) IS7643A (no)
MA (1) MA27381A1 (no)
MX (1) MXPA05001835A (no)
NO (1) NO20050782L (no)
NZ (1) NZ537818A (no)
OA (1) OA12899A (no)
PA (1) PA8577301A1 (no)
PE (1) PE20040992A1 (no)
PL (1) PL375553A1 (no)
PT (1) PT1536782E (no)
RS (1) RS20050078A (no)
SI (1) SI1536782T1 (no)
TN (1) TNSN05042A1 (no)
TW (1) TW200404531A (no)
UA (1) UA77329C2 (no)
UY (1) UY27936A1 (no)
WO (1) WO2004016259A1 (no)
ZA (1) ZA200500369B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
WO2005025563A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
KR100774625B1 (ko) 2003-09-25 2007-11-08 워너-램버트 캄파니 엘엘씨 치료제 베타 아미노산
AU2004276072A1 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Amino acids with affinity for the alpha2delta-protein
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
CA2573128A1 (en) * 2004-07-09 2006-01-26 Warner-Lambert Company Llc Preparation of beta-amino acids having affinity for the alpha-2-delta protein
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
EP1791599A1 (en) * 2004-09-07 2007-06-06 Pfizer Limited Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
TWI531362B (zh) 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
WO2012015027A1 (ja) * 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
WO2013084182A1 (en) * 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
SG11201606858RA (en) 2014-02-21 2016-09-29 Principia Biopharma Inc Salts and solid form of a btk inhibitor
MA41197B1 (fr) 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
CN114195661B (zh) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 一种苯磺酸米洛巴林的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) * 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1047678B1 (en) * 1997-12-16 2004-09-08 Warner-Lambert Company LLC 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
CA2419623A1 (en) * 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
KR100618743B1 (ko) * 2001-04-19 2006-08-31 워너-램버트 캄파니 엘엘씨 융합된 비사이클릭 또는 트리사이클릭 아미노산

Also Published As

Publication number Publication date
HN2003000247A (es) 2007-12-14
GEP20084366B (en) 2008-05-13
IL166415A0 (en) 2006-01-15
DK1536782T3 (da) 2007-07-30
OA12899A (en) 2006-10-13
CR7687A (es) 2005-07-08
EP1536782B1 (en) 2007-04-18
EA200500207A1 (ru) 2005-08-25
ATE359775T1 (de) 2007-05-15
AU2003249476B2 (en) 2008-06-26
EP1536782A1 (en) 2005-06-08
RS20050078A (en) 2007-09-21
GT200300173A (es) 2007-03-29
UA77329C2 (en) 2006-11-15
SI1536782T1 (sl) 2007-08-31
MXPA05001835A (es) 2005-09-30
PL375553A1 (en) 2005-11-28
AP2005003227A0 (en) 2005-03-31
PT1536782E (pt) 2007-06-27
MA27381A1 (fr) 2005-06-01
PE20040992A1 (es) 2004-12-29
TNSN05042A1 (fr) 2007-05-14
UY27936A1 (es) 2004-03-31
NZ537818A (en) 2007-07-27
GB0219024D0 (en) 2002-09-25
DE60313330T2 (de) 2008-01-03
CA2495433A1 (en) 2004-02-26
DE60313330D1 (de) 2007-05-31
IS7643A (is) 2005-01-12
TW200404531A (en) 2004-04-01
ZA200500369B (en) 2006-10-25
WO2004016259A1 (en) 2004-02-26
AU2003249476A1 (en) 2004-03-03
AR040871A1 (es) 2005-04-20
ES2285230T3 (es) 2007-11-16
CN1674884A (zh) 2005-09-28
HRP20050136A2 (en) 2005-06-30
EA007504B1 (ru) 2006-10-27
KR20050042154A (ko) 2005-05-04
BR0313484A (pt) 2005-06-21
ECSP055593A (es) 2005-04-18
JP2006502139A (ja) 2006-01-19
PA8577301A1 (es) 2004-03-10
KR20070009746A (ko) 2007-01-18

Similar Documents

Publication Publication Date Title
NO20050782L (no) Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
PT1487541E (pt) Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
EP1534278A4 (en) NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
MY162110A (en) Caspase inhibitors containing isoxazoline ring
IS8421A (is) Læknisfræðileg meðhöndlun
AU2003205926A1 (en) Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
IL165562A0 (en) Prodrugs of imidazole derivatives for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
WO2003051346A3 (en) Use of selective pde5 inhibitors for treating partial and global respiratory failure
AU2003253498A1 (en) Shower device with tanning device and method for use thereof
ITTO20030672A1 (it) Composizione a base di sostanze naturali utile nel
DE60307891D1 (de) Verwendung eines akariziden pulvers
TW200509921A (en) Alkaline salts
ECSP055715A (es) Utilizacion de pirimetanilo en patogenos resistentes
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
IL181183A (en) Use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia
HUP0401323A2 (hu) IL-18 inhibitorok alkalmazása túlérzékenységi rendellenességek esetén
AU2003294057A1 (en) Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases
AU2003262140A1 (en) Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
PL373000A1 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
HK1079435A1 (en) Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy
AR112121A1 (es) Producto de combinación farmacéutico que comprende toxina botulínica para el tratamiento de la disfunción eréctil
DK1759700T3 (da) Anvendelse af en PDE5-inhibitor til behandling og forebyggelse af hypopigmentlidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application